Amneal Pharmaceuticals, Inc.
AMRX
$12.60
-$0.18-1.41%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.90% | 11.47% | 11.68% | 3.24% | 5.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.90% | 11.47% | 11.68% | 3.24% | 5.50% |
| Cost of Revenue | -8.46% | 10.45% | 12.72% | -2.78% | 4.54% |
| Gross Profit | 25.36% | 13.32% | 9.99% | 14.19% | 7.19% |
| SG&A Expenses | 17.39% | 13.74% | 16.11% | 6.70% | 5.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 98.75% | -103.33% | -290.00% | -- | -5,222.00% |
| Total Operating Expenses | -2.25% | 7.25% | 12.46% | 1.17% | 3.55% |
| Operating Income | 40.11% | 46.73% | 6.19% | 16.20% | 18.61% |
| Income Before Tax | 113.88% | 460.57% | -133.87% | 153.42% | 149.64% |
| Income Tax Expenses | -83.09% | 4.41% | -737.07% | 345.02% | 109.03% |
| Earnings from Continuing Operations | 216.84% | 339.00% | 54.22% | 112.13% | 130.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -26.73% | -40.22% | -32.32% | -22.24% | -24.67% |
| Net Income | 410.50% | 212.85% | 1,618.59% | 273.99% | 113.31% |
| EBIT | 40.11% | 46.73% | 6.19% | 16.20% | 18.61% |
| EBITDA | 14.59% | 13.57% | 0.38% | 13.27% | 14.56% |
| EPS Basic | 402.55% | 211.17% | 1,600.00% | 268.56% | 113.15% |
| Normalized Basic EPS | 214.79% | 214.91% | 609.68% | 10,266.67% | 310.11% |
| EPS Diluted | 384.69% | 208.97% | 1,600.00% | 260.82% | 113.07% |
| Normalized Diluted EPS | 214.53% | 210.05% | 593.55% | 10,000.00% | 294.38% |
| Average Basic Shares Outstanding | 1.60% | 1.49% | 1.46% | 1.50% | 1.23% |
| Average Diluted Shares Outstanding | 1.53% | 5.89% | 4.88% | 1.07% | 5.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |